Study of RiMO-301 with radiation and pembrolizumab before surgery for head and neck cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new treatment for head and neck cancer that can be removed with surgery. It combines an experimental drug (RiMO-301) with targeted radiation and an immunotherapy drug (pembrolizumab) given before surgery, to see if it can shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have head and neck cancer that can be removed with surgery.
- The tumor can be injected with the study drug and can receive radiation therapy.
- You have not had radiation to the same area before, or if you did, it was more than 6 months ago and caused no major problems.
- You have recovered from any side effects of previous cancer treatments.
- You are healthy enough for the study, with adequate blood counts, liver function, and a life expectancy of at least 12 weeks.
- You are not pregnant or breastfeeding, and if you could become pregnant, you agree to use birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination for people whose head and neck cancer has come back after prior radiation. You'll receive an immunotherapy drug (pembrolizumab) plus radiation, then surgery. The goal is to see if this approach can improve how well surgery works.
This trial tests a combination of two immunotherapy drugs (Iparomlimab and Tuvonralimab) with low-dose radiation and chemotherapy for advanced head and neck cancer. It aims to see if this approach can help patients who have not had prior treatment for their cancer.
This trial tests a combination of chemotherapy and an immunotherapy drug called Toripalimab before surgery for certain head and neck cancers. The goal is to see if this approach can reduce the extent of treatment needed while still being effective.
This trial tests a combination of two immunotherapy drugs (IBI110 and sintilimab) with chemotherapy before surgery for people with advanced head and neck cancer that can be removed surgically. The goal is to see if this approach helps shrink tumors and improve outcomes.
This trial studies RiMO-301 injection combined with palliative radiation and a PD-1 immune therapy (pembrolizumab or nivolumab) for head and neck cancer that cannot be fully removed. It aims to see whether this approach can shrink tumors and improve outcomes safely.
This trial tests whether adding pembrolizumab (an immunotherapy drug) to standard chemotherapy before surgery can help people with advanced head and neck cancer. It aims to see if the combination is more effective than chemotherapy alone.
Hear when a new Head and Neck Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.